Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. | Enzalutamide versus abiraterone as a first-line endocrine therapy for castrationresistant prostate cancer ENABLE study for PCa A study protocol for a multicenter randomized phase III trial